Cure My Disease

Don't miss your cure!

 Log in / Sign up

Which additive works best for pain control in brain surgery?

NCT ID NCT07698665

Symptom relief Sponsor: Cairo University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 13, 2026 · Last updated Jul 14, 2026 · Updated 1 time

Summary

This trial tests whether adding ketamine or dexmedetomidine to a standard numbing drug (bupivacaine) in a scalp block improves pain control and reduces opioid use during brain tumor removal. About 80 adults undergoing supratentorial brain tumor surgery will receive one of the two combinations. Researchers will measure pain scores, opioid consumption, and side effects to see which additive works better.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
ketamine and dexmedetomidine (as adjuvants to bupivacaine in scalp block)
What this could lead to
If one adjuvant proves better, it could lead to a standard way to reduce pain and opioid needs during brain tumor surgery.
What could go wrong
This is a small, early-stage comparison in one hospital. Results may not apply to all patients, and both drugs have side effects like sedation or blood pressure changes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 90 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2026

Expected to finish

Jul 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

20 to 60 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age from 20 to 60 years, both sexes, American Society of Anesthesiologists (ASA) physical status II-III, Supratentorial tumor excision, Supine Position. and operation time: less than 6 hours. Exclusion Criteria: * Patient refusal, disturbed consciousness level (Glasgow Coma Scale \[GCS\] \< 15). Patients who required reintubation during the study period, those not extubated. immediately after surgery, or those who awoke with neurological deficits impairing. pain assessments were excluded from the final analysis, history of psychotic disorders or previous surgeries, Poor cognitive function. Postictal state or uncontrolled/recurrent seizures, known allergy to dexmedetomidine or ketamine, difficult intubation (Mallampati score \> III) or multiple intubation attempts, operation duration \> 6 hours, renal dysfunction (creatinine \> 1.2 mg/dL, BUN \> 20 mg/dL), heart block and patients with chronic headache disorders or those receiving chronic analgesic therapy (for \>3 months) were excluded.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute pain are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Acute Pain supratentorial cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute pain Regional anesthesia morbidity Supratentorial brain tumor

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Cairo university

    RECRUITING

    Cairo, Governorate, 002, Egypt

  • Cairo university Hospitals. kasralainy

    RECRUITING

    Cairo, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.